Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Clin Exp Dermatol ; 47(6): 1210-1213, 2022 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-35538888

RESUMEN

We present the case of a 71-year-old woman with widespread comedones since adolescence. Histological examination revealed branching hyperpigmented rete ridges and cystically dilated follicular infundibulum containing laminated keratinous debris. We explore the differential diagnosis in the context of other reticulate hyperpigmentation disorders.


Asunto(s)
Acné Vulgar , Hiperpigmentación , Acné Vulgar/patología , Anciano , Diagnóstico Diferencial , Femenino , Humanos , Hiperpigmentación/diagnóstico , Hiperpigmentación/patología , Piel/patología
2.
Ann Surg Oncol ; 28(2): 1029-1038, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-32542563

RESUMEN

BACKGROUND: Melanoma in-transit metastases (ITMs) are a challenge to treat and associated with systemic disease and poor prognosis. Topical diphencyprone (DPCP), a potent contact sensitizer, is an established treatment for melanoma ITMs. This exploratory study investigated the utility of BRAF mutation status, CD8, PD-1, PD-L1, and TILs distribution as biomarkers for response of ITMs to topical immunotherapy (DPCP). METHODS: The ITM deposits of 40 patients treated with DPCP were subjected to biomarker analysis for BRAF status, CD8 and PD-1 expression on tumor-infiltrating lymphocytes (TILs), and tumor PD-L1 expression. Response to DPCP and overall survival (OS) were compared by biomarker status. RESULTS: After 12 weeks, 10 patients (25%) had a complete response, 12 patients (30%) had a partial response, and 18 patients (45%) had no response. No significant association was found between any individual biomarker and response to DPCP or OS. The BRAF mutation rate was 25% (10/40). All the patients with a complete response had BRAF wild-type tumor. Peritumoral CD8+ T-cells were associated with complete response (P = 0.041). Both CD8+ and PD-1 expressions were highly correlated (P < 0.0001), and the highest levels of PD-1 expression were detected at the peritumoral interface (P = 0.0004). Only two cases were PD-L1-positive, and both had a complete response to DPCP (P = 0.043). CONCLUSION: Patients who have BRAF wild-type tumor are more likely to experience a complete response to DPCP. Peritumoral TILs and PD-1 expressions may predict a better response to DPCP. Expression of PD-L1 may be associated with a complete response to DPCP. A larger prospective study is required.


Asunto(s)
Linfocitos Infiltrantes de Tumor , Melanoma , Antígeno B7-H1 , Biomarcadores de Tumor , Linfocitos T CD8-positivos , Humanos , Inmunoterapia , Melanoma/tratamiento farmacológico , Receptor de Muerte Celular Programada 1 , Estudios Prospectivos , Análisis Espacial
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...